Valuation: Delcath Systems, Inc.

Market Cap 422M 367M 341M 313M 592M 40.27B 601M 4.02B 1.58B 20.05B 1.58B 1.55B 67.23B P/E 2026 *
-21.5x
P/E 2027 * -22.6x
Enterprise Value 422M 367M 341M 313M 592M 40.27B 601M 4.02B 1.58B 20.05B 1.58B 1.55B 67.23B EV / Sales 2026 *
4.09x
EV / Sales 2027 * 3.23x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
-17.07%-34.08% - - 422M
-1.93%+3.91%+0.75%-30.71% 19.68B
+0.73%+4.07%-1.03%-9.28% 16.15B
-1.85%+7.46%-62.34%-49.85% 5.51B
-1.58%+1.26% - - 4.13B
-1.05%+0.53%-11.84%-10.58% 1.85B
+0.38%+1.98%+35.42%+1.72% 1.74B
-0.95%+8.03%-45.77%-62.07% 1.2B
+1.85%+0.92%+76.78%+144.90% 917M
+9.43%+3.00% - - 329M
Average -1.20%+3.07%-1.15%-2.27% 5.72B
Weighted average by Cap. -0.92%+3.90%-6.16%-20.98%

Financials

2026 *2027 *
Net sales 103M 89.75M 83.54M 76.7M 145M 9.86B 147M 985M 386M 4.91B 388M 379M 16.45B 131M 114M 106M 97.04M 183M 12.47B 186M 1.25B 489M 6.21B 491M 480M 20.82B
Net income -21.04M -18.29M -17.03M -15.63M -29.52M -2.01B -29.98M -201M -78.77M -1B -79.04M -77.3M -3.35B -20M -17.39M -16.19M -14.86M -28.06M -1.91B -28.5M -191M -74.88M -951M -75.12M -73.47M -3.19B
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-